Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain

被引:25
作者
Costi, Maria [1 ]
Dilla, Tatiana [1 ]
Reviriego, Jesus [1 ]
Castell, Conxa [2 ]
Goday, Albert [3 ]
机构
[1] Eli Lilly & Co, Dept Clin Res, Madrid 28108, Spain
[2] Generalitat Catalonia, Div Publ Hlth, Dept Hlth, Barcelona, Spain
[3] Univ Autonoma Barcelona, Serv Endocrinol, Hosp Mar, E-08193 Barcelona, Spain
关键词
Type 2 diabetes mellitus; Epidemiology; Treatment; Spain; MICROVASCULAR COMPLICATIONS; RISK-FACTORS; ASSOCIATION; STATEMENT;
D O I
10.1007/s00592-009-0158-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little information is available on the management of patients with type 2 diabetes mellitus (DM2) in regular clinical practice, prior to and at the point of initiating treatment with insulin. The INSTIGATE study provides a description of the clinical profile of the patient with DM2 who begins treatment with insulin in both primary and secondary care. A total of 224 patients who had been diagnosed with DM2, were not responding to oral treatment, and began receiving insulin were included in the INSTIGATE study in Spain. Demographic data were collected, as well as data on macro-and microvascular complications of diabetes and comorbidities, past medical history of diabetes and oral treatment administered, the clinical severity of diabetes (HbA1c concentration) and insulin treatment initiated. Mean age of the sample was 65.4 years and 56.7% were men. There were 87% of patients who had a diagnosis of at least one significant comorbidity, notably hypertension and hyperlipidemia. The patient profile for metabolic syndrome was met by 75.1% of the patients. There was a higher incidence of macro-vascular complications (38.4%) than microvascular complications (16.1%). Prior to insulin initiation, the most recent mean HbA1c was 9.2%. The majority of patients had been treated in the last 12 months with sulfonylureas and/or metformin (69.6 and 57.6%). The most common treatment prior to insulinization was the co-administration of two oral antidiabetics (OADs) (37.5%). Patients with DM2 observed in the study presented with elevated mean HbA1c and body mass index levels, comorbidities and complications related to diabetes at the time of insulin initiation. Changes and adjustments in treatment from diagnosis of diabetes occur when HbA1c levels are far above those recommended by the IDF (International Diabetes Federation), a factor which could be contributing to the development of both macrovascular and microvascular complications in the patient profile described in the study.
引用
收藏
页码:S169 / S175
页数:7
相关论文
共 25 条
[1]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]  
[Anonymous], GLOB GUIDL TYP 2 DIA
[3]  
[Anonymous], 2005, Global Guideline for Type 2 Diabetes
[4]  
[Anonymous], CURR MED RES OP 0130
[5]  
[Anonymous], DIABET MED
[6]  
[Anonymous], 2006, IDF WORLDW DEF MET S
[7]  
[Anonymous], EST DRECA DIET RIES
[8]   Cost-of-illness studies in diabetes mellitus [J].
Ettaro, L ;
Songer, TJ ;
Zhang, P ;
Engelgau, MM .
PHARMACOECONOMICS, 2004, 22 (03) :149-164
[9]   Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591
[10]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743